Company: DVAX
Filing Date: 2025-02-14
Form Type: 8-K
Source: 0001029142-25-000031
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-14
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On February 10, 2025® vaccine. The Supply Agreement replaces entirely the Company’s prior Supply Agreement dated July 27, 2016 with West, which was previously filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Under the Supply Agreement, the Company is obligated to purchase certain volumes of the Product from West, subject to certain adjustments. Pricing for the Product is based on the volume purchased in a calendar year. Such pricing is subject to change during the term of the Supply Agreement in line with a specified price index.

The term of the Supply Agreement is four years from the Effective Date, subject to certain extensions.

Each party has the right to terminate the Supply Agreement prior to its expiration (i) for uncured material breach, and (ii) in the event the other party becomes insolvent, bankrupt, makes an assignment for the benefit of creditors, or otherwise becomes subject to a plan of reorganization.

The foregoing summary description of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Supply Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.